Kathleen M. Schmainda1,
Melissa A. Prah1, Scott D. Rand1, Jennifer Connelly2,
Eric S. Paulson3, Peter S. LaViolette1, Wade Mueller4,
Mark G. Malkin2
1Radiology,
Medical College of Wisconsin, Milwaukee, WI, United States; 2Neurology,
Medical College of Wisconsin, Milwaukee, WI, United States; 3Radiation
Oncology, Medical College of Wisconsin, Milwaukee, WI, United States; 4Neurosurgery,
Medical College of Wisconsin, Milwaukee, WI, United States
Standard measures of tumor volume derived from contrast-enhancing T1-weighted images, or abnormal volumes on T2-weighted images do not reliably predict the response of brain tumors to anti-angiogenic therapies such as bevacizumab. Bevacizumab may result in decreases in enhancing tumor volume without an effect on the tumor biology. In this study we show that standardized relative cerebral blood volume (rCBV) information, derived from DSC MRI, can predict the overall survival (OS) of high-grade gliomas to bevacizumab therapy. If the rCBV is low either before or after treatment, the OS is significantly improved.